The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture ...

Non-invasive therapeutics for anti-osteoporosis treatment and fracture healing are available in both oral and injectable ...

The Osteoporosis Society of the Philippines Foundation Inc. (OSPFI) estimates that by 2050, around 10.2 million Filipinos ...

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of ...

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...

The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.

The FDA has approved two new biosimilars of denosumab-dssb to treat osteoporosis, increase bone mass, prevent ...

A new case report was published in Oncoscience's Volume 12 on February 4, 2025, titled “Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.” ...

The US Preventative Services Task Force task force recommends against vitamin D supplements for fall and fracture prevention ...

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis ...

Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe ...